US FDA's Decade In Review: From Biosimilars To Real-World Evidence

 
• By Brenda Sandburg
Evolutionary Decade at FDA
FDA actions on biosimilars, opioids and real-world evidence shaped the past decade

More from US FDA

More from Agency Leadership